NEW YORK (GenomeWeb) – Illumina's board of directors has authorized the repurchase of up to $250 million of its own common shares in the open market or in privately negotiated transactions, the firm said today.

The company also completed the existing discretionary authorization of $96 million that was repurchased since Illumina reported its third quarter earnings last month.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.